94 results
424B3
RGBP
Regen BioPharma Inc
29 Apr 24
Prospectus supplement
4:08pm
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS
8-K
EX-10.1
RGBP
Regen BioPharma Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:07pm
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS WHEREOF, the parties have
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application … States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application of HemaXellerate qualifies for Orphan
8-K
EX-10.1
lgi95amlx7zghu
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
c9l1f00kt kimo
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
y43e8daqysr 99l
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
uwxj3vjroa9ckj9e
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
oqvv5gpeypp 81gle22
15 May 23
Prospectus supplement
10:25am